Cargando…

Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis

The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanling, Li, Chenglin, Chen, Peizhan, Li, Xiaoguang, Li, Mian, Guo, He, Li, Jingquan, Chu, Ruiai, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691226/
https://www.ncbi.nlm.nih.gov/pubmed/23826116
http://dx.doi.org/10.1371/journal.pone.0066716
_version_ 1782274441941614592
author Liu, Yanling
Li, Chenglin
Chen, Peizhan
Li, Xiaoguang
Li, Mian
Guo, He
Li, Jingquan
Chu, Ruiai
Wang, Hui
author_facet Liu, Yanling
Li, Chenglin
Chen, Peizhan
Li, Xiaoguang
Li, Mian
Guo, He
Li, Jingquan
Chu, Ruiai
Wang, Hui
author_sort Liu, Yanling
collection PubMed
description The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analysis, the association of five common single nucleotide polymorphisms (SNPs) in the VDR gene (ApaI, BsmI, Cdx-2, FokI, and TaqI) with the risk of ovarian cancer. Six eligible studies, with a total of 4,107 cases and 6,661 controls, which evaluated the association of these variants and ovarian cancer risk, were identified from the MEDLINE and PubMed databases. The meta-analysis indicated that FokI was associated with an increased ovarian cancer risk, with a pooled odds ratio (OR) of 1.10 [95% confidence intervals (95% CI) = 1.00–1.20] for CT heterozygotes and 1.16 (95% CI = 1.02–1.30) for TT homozygotes relative to common CC carriers. Carriers of the T allele (also known as the f allele) showed an 11% (pooled OR = 1.11, 95% CI = 1.02–1.21; TT/CT vs. CC) increased risk of ovarian cancer relative to CC carriers. For FokI, no significant heterogeneity between the studies was found (I(2) = 0%, P = 0.62 for the Q test). There was no statistically significant association between the other four variants (ApaI, BsmI, Cdx-2 and TaqI) and risk of ovarian cancer. These data indicate that the polymorphism FokI on the VDR is a susceptibility factor for ovarian cancer. Nevertheless, more studies are warranted to elucidate the underlying mechanisms of the VDR in development of ovarian cancer.
format Online
Article
Text
id pubmed-3691226
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36912262013-07-03 Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis Liu, Yanling Li, Chenglin Chen, Peizhan Li, Xiaoguang Li, Mian Guo, He Li, Jingquan Chu, Ruiai Wang, Hui PLoS One Research Article The vitamin D receptor (VDR) principally mediates the anticancer activities of vitamin D. Various epidemiological studies have investigated the associations of VDR gene polymorphisms with ovarian cancer; however, the results have been inconclusive. In the current study, we evaluated, in a meta-analysis, the association of five common single nucleotide polymorphisms (SNPs) in the VDR gene (ApaI, BsmI, Cdx-2, FokI, and TaqI) with the risk of ovarian cancer. Six eligible studies, with a total of 4,107 cases and 6,661 controls, which evaluated the association of these variants and ovarian cancer risk, were identified from the MEDLINE and PubMed databases. The meta-analysis indicated that FokI was associated with an increased ovarian cancer risk, with a pooled odds ratio (OR) of 1.10 [95% confidence intervals (95% CI) = 1.00–1.20] for CT heterozygotes and 1.16 (95% CI = 1.02–1.30) for TT homozygotes relative to common CC carriers. Carriers of the T allele (also known as the f allele) showed an 11% (pooled OR = 1.11, 95% CI = 1.02–1.21; TT/CT vs. CC) increased risk of ovarian cancer relative to CC carriers. For FokI, no significant heterogeneity between the studies was found (I(2) = 0%, P = 0.62 for the Q test). There was no statistically significant association between the other four variants (ApaI, BsmI, Cdx-2 and TaqI) and risk of ovarian cancer. These data indicate that the polymorphism FokI on the VDR is a susceptibility factor for ovarian cancer. Nevertheless, more studies are warranted to elucidate the underlying mechanisms of the VDR in development of ovarian cancer. Public Library of Science 2013-06-24 /pmc/articles/PMC3691226/ /pubmed/23826116 http://dx.doi.org/10.1371/journal.pone.0066716 Text en © 2013 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Liu, Yanling
Li, Chenglin
Chen, Peizhan
Li, Xiaoguang
Li, Mian
Guo, He
Li, Jingquan
Chu, Ruiai
Wang, Hui
Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title_full Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title_fullStr Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title_full_unstemmed Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title_short Polymorphisms in the Vitamin D Receptor (VDR) and the Risk of Ovarian Cancer: A Meta-Analysis
title_sort polymorphisms in the vitamin d receptor (vdr) and the risk of ovarian cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691226/
https://www.ncbi.nlm.nih.gov/pubmed/23826116
http://dx.doi.org/10.1371/journal.pone.0066716
work_keys_str_mv AT liuyanling polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT lichenglin polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT chenpeizhan polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT lixiaoguang polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT limian polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT guohe polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT lijingquan polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT churuiai polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis
AT wanghui polymorphismsinthevitamindreceptorvdrandtheriskofovariancancerametaanalysis